BACKGROUND: Alterations of DNA methylation are very frequent in prostatic carcinoma. A possible cause underlying altered DNA methylation could be an insufficient level of S-adenosylmethionine as a consequence of nutritional imbalances or of weaker alleles of genes for its synthesis, i.e., encoding methylene-tetrahydrofolate reductase (MTHFR), methionine synthase (MS), and beta-cystathione synthetase (CBS). Therefore, homozygosity or heterozygosity for such weaker alleles may underlie susceptibility to prostatic carcinoma. METHODS: The distribution of the two most frequent MTHFR, MS, and CBS alleles was determined in 132 prostatic carcinoma patients and 150 population controls by restriction fragment length polymorphism-(RFLP) PCR. RESULTS: In the controls, a Hardy-Weinberg equilibrium was observed for each allele pair. No significant differences were observed with respect to age or gender. No significant differences for single genes or combinations were found between prostatic carcinoma patients and controls, although the MTHFR Val allele was slightly overrepresented among the tumor patients. Neither did the allele distribution significantly differ among the prostatic carcinoma patients stratified according to age, clinical stage, or presence of metastases. However, the MTHFR Val allele tended to be associated with higher tumor grade. CONCLUSIONS: In general, the data do not support the hypothesis that weaker alleles in methyl group metabolism genes constitute a major factor in the high prevalence of DNA methylation alterations found in prostatic carcinoma. However, a potential association with the MTHFR genotype deserves further study. Copyright 2000 Wiley-Liss, Inc.
BACKGROUND: Alterations of DNA methylation are very frequent in prostatic carcinoma. A possible cause underlying altered DNA methylation could be an insufficient level of S-adenosylmethionine as a consequence of nutritional imbalances or of weaker alleles of genes for its synthesis, i.e., encoding methylene-tetrahydrofolate reductase (MTHFR), methionine synthase (MS), and beta-cystathione synthetase (CBS). Therefore, homozygosity or heterozygosity for such weaker alleles may underlie susceptibility to prostatic carcinoma. METHODS: The distribution of the two most frequent MTHFR, MS, and CBS alleles was determined in 132 prostatic carcinomapatients and 150 population controls by restriction fragment length polymorphism-(RFLP) PCR. RESULTS: In the controls, a Hardy-Weinberg equilibrium was observed for each allele pair. No significant differences were observed with respect to age or gender. No significant differences for single genes or combinations were found between prostatic carcinomapatients and controls, although the MTHFR Val allele was slightly overrepresented among the tumorpatients. Neither did the allele distribution significantly differ among the prostatic carcinomapatients stratified according to age, clinical stage, or presence of metastases. However, the MTHFR Val allele tended to be associated with higher tumor grade. CONCLUSIONS: In general, the data do not support the hypothesis that weaker alleles in methyl group metabolism genes constitute a major factor in the high prevalence of DNA methylation alterations found in prostatic carcinoma. However, a potential association with the MTHFR genotype deserves further study. Copyright 2000 Wiley-Liss, Inc.
Authors: Jianhui Zhang; Rainer B Zotz; Yan Li; Rui Wang; Sybille Kiel; Wolfgang A Schulz; Denggui Wen; Zhifeng Chen; Liwei Zhang; Shijie Wang; Helmut E Gabbert; Mario Sarbia Journal: J Cancer Res Clin Oncol Date: 2004-07-29 Impact factor: 4.553
Authors: Victoria L Stevens; Carmen Rodriguez; Juzhong Sun; Jeffrey T Talbot; Michael J Thun; Eugenia E Calle Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-12 Impact factor: 4.254
Authors: Ana L S Galbiatti; Mariangela T Ruiz; Luis S Raposo; José V Maniglia; Erika C Pavarino-Bertelli; Eny M Goloni-Bertollo Journal: Arch Med Sci Date: 2010-10-26 Impact factor: 3.318
Authors: Anca Botezatu; Demetra Socolov; Iulia V Iancu; Irina Huica; Adriana Plesa; Carmen Ungureanu; Gabriela Anton Journal: J Cell Mol Med Date: 2013-02-28 Impact factor: 5.310